<DOC>
	<DOCNO>NCT02993536</DOCNO>
	<brief_summary>The purpose study assess evolution B cell genetic surface-marker level high-risk CLL idelalisib-rituximab treatment . The targeted population include 20 subject age 18 old diagnose high-risk CLL . This include patient relapse refractory disease require therapy idelalisib rituximab per FDA label . This observational study peripheral blood sample patient collect pre-determined time point .</brief_summary>
	<brief_title>Clonal Evolution B Cells High-risk CLL After Idelalisib-rituximab</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age 18 Ability provide inform consent Ability provide peripheral blood sample Diagnosis CLL Indication ( ) CLL therapy At least one criterion highrisk disease Disease refractory ( e.g. , response ) least one round chemotherapy Disease relapse ( i.e. , return ) least one round chemotherapy Proven presence 17p deletion within CLL cell Planned receipt idelalisibrituximab per FDA guideline patient 's oncologist Patients meet diagnostic criterion CLL least one indication treatment . Patients receive idelalisib offlabel indication Patients provide informed consent donate peripheral blood tumor sample stem cell core facility Patients provide inform consent collect clinical , prognostic , outcomes data time period treat idelalisibrituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>